AlphAIAlphAI — Financial news for AI agents
investing.com$IMC

IMC Rare Earths reports 73% recovery rate in lab tests

IMC Rare Earths (NYSE: IMC) reported a 73% recovery rate of rare earth elements, excluding cerium, from its Itarantim Project in Brazil using acidified magnesium sulphate. The company aims to evaluate in-situ recovery (ISR) for a more environmentally friendly extraction method. The Itarantim Project contains 1.1 billion tonnes of Inferred Mineral Resource. IMC plans further testing and studies to assess ISR's feasibility.

Original reporting
investing.com
Published Sep 22, 2026, 12:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$IMC
Bullish
medium confidence
Mentioned
$IMC
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IMCBullishLow
01

Why it matters

The disclosed recovery rates suggest technical feasibility, but commercial viability remains uncertain.

02

Market read

First public disclosure of ISR test results; may influence investor perception of IMC Rare Earths.

03

What to watch

Uranium/thorium limits, inferred resource status, and capital requirements for pilot testing.

Relevance 5/10Novelty 7/10Timing: today

Background

IMC Rare Earths is a small-cap miner developing in‑situ recovery (ISR) technology for rare earths in Brazil.

Company-level read

Ticker impact

$IMCBullishMedium confidence
Context

IMC Rare Earths disclosed lab tests recovering 73% of rare earths from its Brazil project.

Expected impact

Potential modest upside if market views ISR as viable.

Evidence & confidence

First disclosure of extraction efficiency; scale is limited and project remains inferred resource.

Market effects

Sector

May boost sentiment for rare‑earth and clean‑tech mining stocks.

Regional

Highlights Brazil's potential in critical minerals supply chain.

Global

Limited; rare‑earth sector interest but no broad market shift.

Counterpoint

What could challenge this read

Lab results may not translate to field scale; ISR risks could outweigh benefits.

Key entities

  • Executive
    Frank Scolaro

    CEO and Chair of IMC Rare Earths, quoted on the test results.

  • Research Institution
    University of Brighton

    Conducted the laboratory leaching tests.

Read at source← All news

Related articles

$BEMedAI 8/10

NTT Data Signs 900-Megawatt Bloom Energy Deal for Data Centers

NTT Data will deploy 900 MW of Bloom Energy's fuel-cell systems in data centers globally, starting in 2027. Bloom calls it their largest international project. NTT will use the systems as primary power. Bloom previously announced a deal with Oracle for up to 2.8 GW. The IEA projects global data-center electricity demand to double by 2030.

theminermag.com
$MMSIMedAI 8/10

At six months, 92.7% of patients needed no repeat procedure for the treated dialysis-access blockage.

Merit Medical Systems (MMSI) reported 6-month data from the WRAP Global registry, showing 92.7% target lesion primary patency and 76.7% access circuit primary patency for its WRAPSODY CIE device in arteriovenous fistula patients. Results exceeded those from prior trials, according to the company. The device is FDA-approved and commercially available in the U.S., EU, and other regions.

stocktitan.net
$MTVAHighAI 8/10

MetaVia Reports 68% Placebo-Adjusted Liver Fat Reduction for DA-1726

MetaVia reported interim Phase 1 data for DA-1726, showing a 68% placebo-adjusted reduction in liver fat, 13.5% weight loss, and 0.24% HbA1c reduction. All participants with liver steatosis achieved MRI-PDFF below 5% by Day 109. No new gastrointestinal adverse events were reported after Week 9. Full Part 3A and 3B data is expected in Q1 2027, with a Phase 2 study planned for H2 2027.

tradingview.com
$MTVAHighAI 8/10

MetaVia reports 68% liver fat reduction in phase 1 trial

MetaVia Inc. (MTVA) reported interim Phase 1 trial results for DA-1726, showing a 68% placebo-adjusted reduction in liver fat and 13.5% body weight reduction. The trial included 15 participants treated with DA-1726 and 4 on placebo. The company plans to report full data in Q1 2027 and initiate a Phase 2 study in H2 2027. Gastrointestinal adverse events were reported in 9 participants, with one serious case of severe vomiting.

investing.com